---
title: CDMO Daily News — September 18, 2026
slug: daily-news-2026-09-18-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: September 18 CDMO daily: Piramal Pharma Solutions Deploys 4.3 MWp Solar Plant at UK Drug Substance/Product Facility; ProBio and Kun Tuo (IQVIA) Launch…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-09-18-cdmo
published_at: 2026-09-18T00:02:20.220Z
last_updated: 2026-09-18T00:03:04.997Z
---

### [Piramal Pharma Solutions](/companies/piramalpharmasolutions) Deploys 4.3 MWp Solar Plant at UK Drug Substance/Product Facility
- [Piramal Pharma Solutions](/companies/piramalpharmasolutions) is installing a 4.3 MWp ground-mounted solar plant at its integrated Morpeth, UK facility, expected to generate 3,950 MWh annually.
- The solar installation will cover approximately 22% of the site's electricity demand and avoid an estimated 20,000 tCO₂e emissions over 25 years, with operations beginning Q1 2027.

**Operational Impact**

Piramal's Morpeth facility will reduce grid electricity dependency by 22% through onsite solar generation, lowering operational costs and enhancing energy supply stability for integrated drug substance and product manufacturing.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/piramal-pharma-solutions-adds-4-3-mwp-solar-plant-at-uk-facility)*

---

### [ProBio](/companies/probio) and Kun Tuo (IQVIA) Launch Integrated CDMO-CRO Partnership for China Biologics Development
- [ProBio](/companies/probio) (CDMO) and Kun Tuo (IQVIA's China CRO) formed a strategic partnership to provide end-to-end support for biologics and cell/gene therapy development in China, covering CMC, non-clinical studies, and clinical operations.
- ProBio has manufactured over 1,000 GMP batches and supported 90+ IND/IIT programs; Kun Tuo has managed 1,400+ clinical trials and employs ~1,000 staff across China's clinical research network.
- The integrated model aims to streamline development pathways for global sponsors by coordinating manufacturing, regulatory, and clinical trial execution through a single partnership.

**Operational Impact**

[ProBio](/companies/probio)'s China CDMO-CRO integration with Kun Tuo expands integrated development capacity for CGT sponsors entering China, reducing coordination friction between manufacturing scale-up and clinical site engagement.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/probio-and-kun-tuo-partner-on-integrated-cdmo-cro-solutions-in-china)*

## References

1. [PharmaSource RSS — Piramal Pharma Solutions Deploys 4.3 MWp Solar Plant at UK Drug Substance/Product Facility](https://pharmasource.global/content/news/cdmo-news/piramal-pharma-solutions-adds-4-3-mwp-solar-plant-at-uk-facility)
2. [PharmaSource RSS — ProBio and Kun Tuo (IQVIA) Launch Integrated CDMO-CRO Partnership for China Biologics Development](https://pharmasource.global/content/news/cdmo-news/probio-and-kun-tuo-partner-on-integrated-cdmo-cro-solutions-in-china)

Source: https://www.cdmo.directory/posts/daily-news-2026-09-18-cdmo